Home
Medivation

Medivation Market Share Analysis for November 2025

Health > Biotechnology and Pharmaceuticals

Domainmedivation.com

Year Founded2003

Employees501 - 1000

Annual Revenue$500M - $1B

Medivation

Medivation (including company regionals)

medivation.com

See more website traffic and engagement information

Medivation Revenue up to November 2025 is 500M - 1B

revenue generated by Medivation top domains

Medivation top domains revenue over 3 years

Revenue for Medivation top domains

medivation.com500M - 1B

See more with Sales Intelligence

Total visits to Medivation's top domains

Understand Medivation market share and potential market reach.

Total visits last 3 months

No Data to Display

Avg. visit duration in Medivation's top domains

Analyze Medivation engagement metrics.

Average visit duration last 3 months

No Data to Display

Avg. pageviews on Medivation's top domains

See how Medivation keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

No Data to Display

Medivation top competitors by domain

Top similar sites in November 2025, ranked by their affinity

exelixis.comCompany NameExelixisEmployees1001 - 5000HQUnited States, California, AlamedaAnnual revenue> $1BTotal visits25.2KHealth > Biotechnology and Pharmaceuticals

Top technologies used by Medivation

These are the website technologies, by industry, used by Medivation top domains

Advertising (7)

Facebook Custom Audiences

Social (4)

Instagram

Mobile (3)

Meta Viewport

Audio Video Media (2)

YouTube

More Technologies

4

See all

News & Signals from Medivation

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsMatthew Panuwat leaves Medivation as executive.On april 5, following an eight-day trial, a jury deliberated for just over two hours before finding that the SEC established by a preponderance of evidence that former Medivation executive Matthew Panuwat is liable for insider trading by trading not in Medivation's stock but instead its alleged competitor Incyte's stock (minutes after learning from his CEO that pfizer was close to acquiring Medivation).

NewsMedivation partnered with Astellas Pharma Inc on Jan 1st '05.Medivation Inc. licensed the patent and collaborated with Astellas to develop that research into a drug.

NewsMedivation has issues with breach of Panuwat’s fiduciary duties.The court next held that the SEC had sufficiently alleged a breach of Panuwat’s fiduciary duties to Medivation under the misappropriation theory of liability: he had used MNPI obtained from his employer for his personal benefit in violation of an agreement not to do so.